Soleno Therapeutics (SLNO) Ends 26% Lower After Q3 Earnings [Yahoo! Finance]
Soleno Therapeutics, Inc. (SLNO)
Last soleno therapeutics, inc. earnings: 5/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.soleno.life/investor-overview
Company Research
Source: Yahoo! Finance
Soleno Therapeutics extended its losing streak to a 5th consecutive day on Wednesday, slashing 26.59 percent to close at $46.87 apiece as investors appeared to have priced in a strong earnings performance in the third quarter of the year. The maker of the first and only FDA-approved drug for hyperphagia said in an updated report that it swung to a net income of $26 million, or a 134 percent improvement from the $76.6 million net loss in the same period last year. It also incurred revenues of $66 million during the quarter. Soleno Therapeutics (SLNO) Ends 26% Lower After Q3 Earnings kurhan / shutterstock.com “Our strong third quarter results reflect growing awareness of the compelling efficacy and safety profile of Vykat XR within the PWS community,” said Soleno Therapeutics Inc. (NASDAQ:SLNO) Chairman and CEO Anish Bhatnagar. “As the first and only FDA-approved therapy to treat the hallmark symptom of PWS—hyperphagia—in patients 4 years and older, Vykat XR can offer a new o
Show less
Read more
Impact Snapshot
Event Time:
SLNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLNO alerts
High impacting Soleno Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SLNO
News
- Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred LossesPR Newswire
- Soleno Therapeutics Announces the Passing of Board Member William G. Harris [Yahoo! Finance]Yahoo! Finance
- Soleno Therapeutics Announces the Passing of Board Member William G. HarrisGlobeNewswire
- Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred LossesGlobeNewswire
- Soleno Therapeutics (SLNO): Does Current Valuation Signal Opportunity or Caution for Investors? [Yahoo! Finance]Yahoo! Finance
SLNO
Earnings
- 11/4/25 - Beat
SLNO
Sec Filings
- 11/19/25 - Form 4
- 11/19/25 - Form 3
- 11/14/25 - Form SCHEDULE
- SLNO's page on the SEC website